Fundraising Strategy: Decide What Capital Must Buy

A fundraising round can close successfully and still be a bad company decision.

The money may fund activity without resolving the risk that matters. The valuation may look flattering while the rights attached to it narrow the founders’ future choices.

Or the company may raise because fundraising feels like proof, then discover that capital has made an untested operating model more expensive to change.

Fundraising strategy is not a pitch-deck sequence. It is the decision to exchange part of the company’s economics and governance for a specific set of options that cash can create.

The work starts before investor outreach: decide why this form of capital fits, what must become true before the next financing decision, and which rights the company is prepared to share.

Decide whether equity belongs in the problem

“We need money” describes a cash condition. It does not identify the right instrument.

Name the constraint the financing must change. It may be the time needed to resolve market uncertainty, a working-capital gap, a regulated development cost, a distribution opportunity, or an operating investment with a delayed return.

Then compare plausible responses:

• reduce or sequence the commitment;

• finance it from revenue;

• use a grant, customer prepayment, or commercial partnership;

• use debt where repayment risk and terms fit the cash flows;

• raise equity or an instrument that may convert into equity;

• decline the opportunity and preserve control.

This article cannot determine the appropriate instrument or legal route for a particular company. Those choices depend on jurisdiction, entity, investors, and facts, and require qualified legal and financial advice.

The US Securities and Exchange Commission notes that raising from investors involves offering and selling securities, usually under a registered offering or an available exemption.[1]

That is US federal information, not global legal guidance. Its strategic implication travels: investor outreach is not merely marketing. It is part of a regulated transaction whose route should be understood before communication begins.

Give the capital one job

A round should buy a meaningful change in the company’s decision position.

“Expand the team and accelerate growth” lists spending and ambition. It does not say which uncertainty the spending resolves or which next choice becomes possible.

Use a capital thesis:

We are considering [instrument] now because [constraint] prevents [specific option]. The capital would fund [bounded commitments] to establish [decision-relevant evidence or capability] before [decision date].

The thesis should survive three questions:

1. What could the company decide after this capital that it cannot decide now?
2. Which observation would show that the thesis is failing?
3. What would remain valuable or recoverable if the expected outcome does not arrive?

This is distinct from product growth strategy, which chooses where new value should come from. Financing decides whether outside capital is the right way to fund that path.

Build a runway model around decisions

Runway is not one number. It is a set of cash scenarios attached to obligations and decision dates.

Start with the bank position and the timing of cash, not booked revenue. Model expected receipts, payroll, taxes, vendors, financing costs, contractual obligations, and costs required to close or reduce an initiative.

Official UK business guidance describes a cash-flow forecast as the timing of money entering and leaving a business and recommends using evidence the company can safely predict.[2]

The guidance suggests a twelve-month forecast for funding applications. That period is not a universal startup runway target and should not be borrowed as one.

Build at least three internally coherent cases:

• operating case: assumptions the company is prepared to manage against;

• adverse case: slower receipts, higher costs, or delayed evidence;

• choice case: spending the company can stop or defer to preserve a valuable option.

Mark the dates when the company loses an option. The last responsible date to start a financing process may arrive long before cash reaches zero.

The same is true for cost reduction. Savings that require contract notice, customer migration, or staff consultation cannot be invoked on the day the bank balance becomes uncomfortable.

Early-Stage Startup Challenges helps distinguish a cash symptom from the uncertainty or operating constraint underneath it.

Turn milestones into claims, not theatre

Investors may use familiar milestones such as revenue, retention, regulatory progress, or signed customers. A founder still needs to know what each milestone establishes for this company.

A useful milestone has five parts:

• claim: the belief that should become more or less credible;

• evidence: the observation and relevant population;

• capability: what the company must be able to do repeatedly;

• decision: what the evidence may authorise next;

• boundary: what remains unproved.

Several negotiated pilots may establish access to buyers and a willingness to test under special conditions. They do not automatically establish repeatable acquisition, economical delivery, or retention.

Choose milestones that retire the risk blocking the next company decision. Link hiring and recurring spend to those milestones rather than assuming the whole plan deserves funding on day one.

Lean MVP for Startups explains how evidence should earn each increase in product commitment. A financing plan applies the same discipline across the company.

Size the round from the work and the options

There is no responsible universal formula such as “raise for eighteen months”. A standard interval ignores the company’s evidence cycle, costs, revenue shape, legal work, and ability to change course.

Estimate the capital required to reach each decision-relevant state. Include the cost to prepare, operate, interpret, and close the work, not only the build cost.

Then add explicit allowances for risks the company has chosen to retain. Do not hide every uncertainty inside one unexplained percentage.

A round-size review should show:

• opening cash and committed inflows;

• recurring and one-off spending by decision stage;

• timing ranges for hiring and receipts;

• obligations that survive a stopped initiative;

• the minimum cash needed to execute an adverse decision;

• fundraising and transaction costs;

• choices available under each scenario.

The output is not a claim that the future is predictable. It is a map of when management still has room to act.

“Lean” financing is not the smallest cheque. It is enough capital for a coherent decision path without pretending every later commitment is already earned.

Read the term sheet as an operating design

Valuation is only one variable in a financing.

Kaplan and Strömberg’s study of real venture contracts found that cash-flow, voting, board, liquidation, and other control rights can be allocated separately and made contingent on performance.[3]

The study examines venture-capital contracts from an earlier period and does not prescribe acceptable terms for a current company. Its durable warning is structural: percentage ownership does not fully describe control or economic outcome.

Model the proposed financing across at least these areas:

• ownership before and after the round on a fully diluted basis;

• how options or other reserved equity affect existing holders;

• conversion and future-financing mechanics;

• liquidation preference and participation economics;

• board composition, voting, and protective provisions;

• information, inspection, pro-rata, and registration rights;

• founder and employee vesting or transfer restrictions;

• conditions that change rights, control, or closing.

Run scenarios for an ordinary exit, a weak exit, another round, a down round, and a company that needs more time without new capital. The point is not to predict an exit value.

The point is to see which party decides, who receives what, and which options remain under states less flattering than the pitch.

The National Venture Capital Association’s model documents include a certificate of incorporation, stock purchase agreement, investors’ rights agreement, voting agreement, and right-of-first-refusal and co-sale agreement.[4]

They are US industry models with alternative provisions, not a neutral substitute for counsel or evidence that a term is fair. Their breadth shows why a term sheet cannot be reduced to valuation and cheque size.

Select a governance counterpart, not a logo

An investor can become a board member, information recipient, follow-on decision-maker, reference, recruiter, and participant in difficult company choices.

Evaluate the working relationship under stress, not only the quality of the fundraising conversation.

Ask founders from the investor’s portfolio about:

• behaviour when targets were missed;

• preparation and conduct in board discussions;

• help that was actually available;

• conflicts between fund incentives and company needs;

• follow-on decisions in ambiguous cases;

• respect for management boundaries;

• the partner’s availability after the deal.

Gompers and colleagues surveyed 885 institutional venture capitalists at 681 firms across sourcing, selection, valuation, structure, post-investment activity, and exits.[5]

The evidence is self-reported by institutional VCs and does not reveal what one investor will do. It supports only a bounded point here: investment selection and the post-investment relationship are parts of one system.

Do not optimise for prestige if the company’s financing thesis requires a partner with different incentives, expertise, or follow-on capacity.

Build an evidence room, not a document dump

A data room should let a reviewer trace material claims to current records.

Organise it around the financing thesis:

• corporate structure, ownership, and prior instruments;

• historical accounts, cash position, obligations, and forecast assumptions;

• customer contracts, revenue quality, concentration, and delivery duties;

• product evidence, cohort definitions, and measurement limitations;

• intellectual property, employment, privacy, security, and regulatory records;

• material risks, disputes, dependencies, and unresolved decisions.

Keep a claim ledger beside the files. For each major statement, note the source, date, population, calculation, owner, and limitation.

Evidence quality matters more than decorative completeness. A named gap with an owner is more credible than a polished chart whose denominator nobody can reconstruct.

Run the process as a sequence of company decisions

Investor conversations should happen in a coherent window because facts, terms, and management attention otherwise drift. That does not justify invented urgency or claims that another offer exists.

Track each conversation by decision state:

fit assessed
→ thesis discussed
→ evidence reviewed
→ partner and firm diligence
→ terms compared
→ legal and financial review
→ company decision

Define stop conditions before the process begins.

Stop, resize, or change route if the thesis fails, runway cannot support completion, terms break a governance boundary, or new evidence makes the funded plan incoherent.

Fundraising consumes attention. Record which operating decisions remain with the team, which move to a named founder, and which work pauses during the process.

Product Portfolio Optimization provides a wider method for funding the next decision rather than defending every initiative already in motion.

A fictional financing decision

Consider a fictional B2B startup that helps laboratories schedule equipment and retain maintenance records. The example is invented and claims no result.

The company has several paid installations, but each new site requires founder-led configuration. A larger customer asks for a multi-site deployment and a documented response process.

The founders first describe the need as “capital to scale sales”. The constraint map shows a different problem: they do not know whether configuration can become repeatable without weakening control over maintenance records.

Their capital thesis funds a bounded multi-site implementation, a configurable permissions model, evidence about support work, and enough operating capacity to make a follow-up decision.

The milestone is not a signed enterprise logo. It is a traceable claim about repeatable setup, trustworthy records, delivery cost, and the customer’s willingness to operate under a standard boundary.

The adverse case assumes slower rollout and no new round. It preserves the cash required to support existing sites and close the new path without abandoning retained records.

During term review, the founders model ownership and liquidation outcomes, but also board authority, information rights, and decisions requiring investor consent.

They reference-check the proposed board partner in companies that missed a plan, not only in the investor’s strongest portfolio examples.

No conclusion is supplied. The example shows how the decision changes when capital, evidence, obligations, dilution, and governance are reviewed together.

The round is a means, not the milestone

Closing produces cash and a new set of obligations. It does not prove demand, product quality, or company health.

A sound fundraising strategy can explain:

• why this instrument fits the constraint;

• what decisions the capital is meant to unlock;

• how runway changes under adverse conditions;

• which claims define progress;

• what ownership, economic, and control rights change;

• why the investor fits the governance work;

• which conditions would stop or reshape the process.

The best decision may be a smaller round, a different instrument, a delayed process, or no external capital. Decide what money must buy before deciding how to sell the story.

Sources

1. US SEC: Pathways to Raise Capital From Investors (US federal information, not cross-jurisdiction legal advice)

2. Business.gov.uk: Preparing for funding applications (official general guidance on cash-flow forecasts, not a runway benchmark)

3. Kaplan and Strömberg: Financial Contracting Theory Meets the Real World (empirical analysis of VC contracts from an earlier market period)

4. National Venture Capital Association: Model Legal Documents (US industry models with alternative terms, not legal advice)

5. Gompers et al.: How Do Venture Capitalists Make Decisions? (survey of 885 institutional VCs at 681 firms; self-reported evidence)

Read next

• Lean MVP for Startups: Spend Runway on Evidence

• Early-Stage Startup Challenges: Diagnose Before You Act

• Product Growth Strategies: How to Choose the Right Growth Path